Therapy Area topics
Cardiovascular
Medtronic faces a denervation delay
And when the long-awaited trial does finally report it will have to be a smash hit.
Merck & Co justifies paying up for Acceleron
But with the obvious buyer, Bristol, having apparently been outbid, there might be questions over Acceleron’s takeout price.
Central Nervous System
ANA 2021 – Ionis rocked by tofersen flop
After the Valor defeat, the group and its partner Biogen will hope that going earlier could improve the amyotrophic lateral sclerosis project’s chances.
Diabetes
Go or no go? A first for Nefecon
Calliditas is hoping for its first approval, while Abbvie is gearing up to enter the crowded migraine space with an oral anti-CGRP project.
Digital Health
Medtech venture funding hits new heights
Private device makers enjoy the biggest quarter for four years – and the average deal is larger than ever.
Oncology
Agenus investors wake up to inevitability
The stock crashed on Friday as balstilimab’s US filing was pulled – an event that had been entirely foreseeable.
Respiratory
Boehringer takes a different approach in cystic fibrosis gene therapy
Deals this week with a UK consortium and Oxford Biomedica see the group bet on lentiviral vectors.
The lung fibrosis pipeline thins
This month Pliant Therapeutics claimed a win in idiopathic pulmonary fibrosis, but other projects have fallen by the wayside.
Various
Go or no go? A first for Nefecon
Calliditas is hoping for its first approval, while Abbvie is gearing up to enter the crowded migraine space with an oral anti-CGRP project.
